Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic
ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central nervous system (CNS) homing peptides to treat Alzheimer’s disease and the onset of dementia.
Alzheimer’s disease has proven to be a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in cognition and memory function. The disease leads to deficits and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. Alzheimer’s disease is also accompanied by concomitant behavioral, emotional, interpersonal, and social deterioration. Treatment of Alzheimer’s remains largely inadequate.
“There is still an unmet need for effective methods to prevent and treat Alzheimer’s disease. Our hope is a targeted delivery of a therapeutic agent to cells that cause disease or are affected by a disease can improve the treatment of Alzheimer’s and dementia,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
Silo Pharma continues to explore the use of its CNS homing peptides along with its study of other novel therapeutics currently in preclinical studies.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com